Subscribe
Op-Eds

FDA must decide if a biosimilar rose by any other name is still a rose

By Peter Pitts
Published
Add Washington Examiner on Google
FDA must decide if a biosimilar rose by any other name is still a rose

“A good name is better than precious ointment.” – Ecclesiastes 7:1

Federal approval of biosimilars promises to be a very good thing, but the devil is in the details. Unfortunately, we’re seeing a disturbing trend relating to one of those key details: naming nomenclature.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

FDA Health Pharmaceutical Industry